Business context and reporting period
The supplied filing is Cara Therapeutics, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2016—not a Tvardi Therapeutics filing. The company is a clinical-stage biopharmaceutical developer of CR845 for pain and pruritus and had no products for sale.
Financial results and position
Amounts below are in millions of dollars except per-share data. Revenue was $0 in Q3 2016, versus $2.44 million in Q3 2015; nine-month revenue was $0.086 million versus $3.803 million. The 2016 nine-month revenue was clinical compound sales; prior-year revenue primarily reflected license, milestone and collaboration revenue.
- Losses: Q3 net loss was $11.542 million ($0.42 per share), compared with $4.787 million ($0.19) in Q3 2015. Nine-month net loss was $35.308 million ($1.29 per share), versus $15.160 million ($0.64).
- Expenses: Q3 R&D expense rose 73% to $9.671 million and G&A rose 13% to $2.102 million. Nine-month R&D rose 112% to $28.976 million and G&A rose 28% to $7.195 million, reflecting clinical development, manufacturing, toxicology and personnel costs.
- Cash and liquidity: At September 30, cash and cash equivalents were $5.426 million and marketable securities were $65.994 million, totaling $71.420 million unrestricted. Current assets were $77.018 million and current liabilities $6.825 million. Management expected available cash and securities to fund planned operations through the end of Q1 2018, excluding potential collaboration milestones.
- Cash flow: Nine-month operating cash use was $34.193 million, compared with $17.310 million in 2015. Investing activities provided $24.478 million, largely from securities maturities and sales; financing provided $0.040 million. Cash and cash equivalents declined $9.675 million.
- Debt and obligations: The balance sheet reports no debt balance. Operating lease commitments totaled $9.241 million, including $8.268 million for the Stamford lease. Current liabilities included a $0.998 million accrued liability for the vacated Shelton facility.
Material changes versus the prior comparable period
- Revenue declined sharply because significant Maruishi and CKD license, milestone and deferred collaboration revenue recognized in 2015 did not recur.
- Higher clinical-development spending increased operating losses and cash used in operations. Nine-month R&D spending more than doubled year over year.
- Cash and marketable securities fell from $106.741 million at December 31, 2015 to $71.420 million at September 30, 2016. The comparison includes the prior-year follow-on offering proceeds.
- Common shares outstanding increased modestly, from 27.255 million at year-end 2015 to 27.283 million at September 30, 2016.
Outlook, commentary, risks and unusual items
- Management expected R&D expense to remain near its current level through 2018 and anticipated higher G&A expense to support development and possible commercialization. The company stated that additional capital would be needed to meet all development objectives; financing may be unavailable or dilutive.
- The adaptive Phase 3 IV CR845 postoperative-pain trial was placed on FDA clinical hold in February 2016 after a protocol stopping rule for elevated serum sodium was triggered. The FDA removed the hold in April; the trial resumed in June with a revised two-dose design. An interim analysis was expected in the first half of 2017.
- Top-line results were expected in 2017 for the Oral CR845 osteoarthritis Phase 2b trial (first half), the uremic-pruritus Phase 2/3 trial’s Part A (first quarter), and an oral-CR845 hemodialysis pharmacokinetic safety trial (first quarter). These are forward-looking expectations, not reported outcomes.
- Relocation from Shelton to Stamford resulted in $0.899 million of accelerated leasehold-improvement amortization and a $1.312 million cease-use liability accrual in 2016. The Shelton lease runs through October 2017; the Stamford lease runs through October 2023.
- Key risks include clinical-trial safety, efficacy and timing; regulatory approval; commercialization and reimbursement; competition; dependence on collaborators and third parties; intellectual-property protection; and the need for additional financing. The filing reported no material legal proceedings, no material changes to previously disclosed risk factors, and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for Cara Therapeutics, Inc., despite the Tvardi Therapeutics request metadata.
- Track actual cash burn and whether the stated runway through Q1 2018 remains achievable, given planned trial costs and the company’s stated need for additional capital.
- Verify clinical-trial progress, safety findings and reported data against the stated 2017 expectations, especially for IV CR845 and Oral CR845.
- Review the conditions and timing for potential Maruishi and CKD milestones; the filing states receipt is uncertain and excludes them from its runway estimate.
- Monitor the Shelton lease accrual and remaining lease commitments, as well as any subsequent financing or share dilution.